Hematris Wound Care GmbH, a Munich, Germany-based company that develops, manufactures and commercialises products in the area of wound care, has received a €2.0m equity financing from Aurelia Private Equity and KfW.
The funds will be used to launch on the market the company’s flagship product, the wound biodegradable patch Hematrix®, which stops severe, even arterial injury-related bleeding and external bleeding caused by surgical intervention in a few minutes.
According to Georg Langer, Head of Sales at Hematrix, Hematrix® will be marketed in both medial/clinical and emergency and rescue environments.
Backed by seed financing from High-Tech Gründerfonds and Berliner Peppermint Holding GmbH, the company developed the preclinical prototype of the patch into a marketable product. This phase followed clinical studies on patients, which achievied impressive results in stopping arterial bleeding.